Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction : vimarsana.com

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025


Acquisition adds taletrectinib, a next-generation,...

Related Keywords

United States , Japan , New York , China , Shanghai , Decheng , Guangdong , San Francisco , California , Cayman , 00 , Cayman Islands , Daiichi Sankyo , Junyuan Jerry Wang , Innovent Biologics , Nuvation Bio , Walkers Cayman , Morrison Foerster Llp , Exchange Commission , Morrison Foerster , Drug Administration , China National Medical Products Administration , Davis Polk Wardwell , Anheart Therapeutics Ltd , Nuvation Bio Inc , Medivation Inc , Newg Lab , Anheart Therapeutics , David Hung , Chief Executive Officer , Min Cui , Managing Director , Decheng Capital , Non Voting Convertible Preferred Stock , Nuvation Bio Stockholder Approval , Nuvation Bio Stockholder , Breakthrough Therapy Designations , National Medical Products Administration , Priority Review Designation , New Drug Applications , Fangda Partners , Heart Therapeutics , Priority Review Designations , Greater China , Nippon Kayaku ,